Browse GDF9

Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00019 Transforming growth factor beta like domain
Function

Required for ovarian folliculogenesis. Promotes primordial follicle development. Stimulates granulosa cell proliferation. Promotes cell transition from G0/G1 to S and G2/M phases, through an increase of CCND1 and CCNE1 expression, and RB1 phosphorylation. It regulates STAR expression and cAMP-dependent progesterone release in granulosa and thecal cells. Attenuates the suppressive effects of activin A on STAR expression and progesterone production by increasing the expression of inhibin B. It suppresses FST and FSTL3 production in granulosa-lutein cells.

> Gene Ontology
 
Biological Process GO:0001553 luteinization
GO:0001555 oocyte growth
GO:0001558 regulation of cell growth
GO:0006869 lipid transport
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0009914 hormone transport
GO:0009994 oocyte differentiation
GO:0010817 regulation of hormone levels
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
GO:0010876 lipid localization
GO:0016049 cell growth
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0022602 ovulation cycle process
GO:0023061 signal release
GO:0030308 negative regulation of cell growth
GO:0030509 BMP signaling pathway
GO:0032368 regulation of lipid transport
GO:0035929 steroid hormone secretion
GO:0042698 ovulation cycle
GO:0042701 progesterone secretion
GO:0044057 regulation of system process
GO:0044060 regulation of endocrine process
GO:0045137 development of primary sexual characteristics
GO:0045926 negative regulation of growth
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048477 oogenesis
GO:0048511 rhythmic process
GO:0048588 developmental cell growth
GO:0048599 oocyte development
GO:0048608 reproductive structure development
GO:0050886 endocrine process
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation
GO:0060395 SMAD protein signal transduction
GO:0060986 endocrine hormone secretion
GO:0061458 reproductive system development
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:2000194 regulation of female gonad development
GO:2000241 regulation of reproductive process
GO:2000831 regulation of steroid hormone secretion
GO:2000870 regulation of progesterone secretion
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0008083 growth factor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04913 Ovarian steroidogenesis
Reactome -
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GDF9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GDF9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GDF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1410.4
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2110.572
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0850.763
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.520.0466
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.90.101
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0420.439
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2450.454
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.110.845
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3760.537
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.350.442
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3540.577
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0350.81
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GDF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GDF9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GDF9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GDF9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GDF9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GDF9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GDF9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGDF9
Namegrowth differentiation factor 9
Aliases GDF-9; Growth/differentiation factor 9
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GDF9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.